作者
Anna Buda-Nowak, Jakub Kucharz, Paulina Dumnicka, Marek Kuzniewski, Roman Maria Herman, Aneta L Zygulska, Beata Kusnierz-Cabala
发表日期
2017/4
期刊
Medical Oncology
卷号
34
页码范围
1-4
出版商
Springer US
简介
Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the incidence of hypothyroidism and treatment outcome in patients treated with TKI. This study evaluates whether development of hypothyroidism is a predictive marker of progression-free survival (PFS) in patients with mRCC treated with sunitinib. Twenty-seven patients diagnosed with clear cell mRCC, after nephrectomy and in ‘good’ or ‘intermediate’ MSKCC risk prognostic group, were included in the study. All patients received sunitinib as a first-line treatment on a standard schedule (initial dose 50 mg/day, 4 weeks on, 2 weeks off). The thyroid-stimulating hormone serum levels were obtained at the baseline and …
学术搜索中的文章
A Buda-Nowak, J Kucharz, P Dumnicka, M Kuzniewski… - Medical Oncology, 2017